K 134Alternative Names: K-134; OPC-33509
Latest Information Update: 21 Aug 2015
At a glance
- Originator D. Western Therapeutics Institute
- Developer Kowa
- Class Antiplatelets; Antithrombotics; Organic chemicals; Quinolines; Small molecules; Urea compounds
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Arteriosclerosis obliterans